𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin

✍ Scribed by Kathrin Overbeck; Daniel Genné; Alain Golay; Francesco Negro


Book ID
116651607
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
102 KB
Volume
49
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Merimepodib, pegylated interferon, and r
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a